2,315 results on '"Stock, Wendy"'
Search Results
52. Air Pollutant Impact on Disease Characteristics and Outcomes in Patients with Acute Myeloid Leukemia
53. Data from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
54. Supplementary Figures 1-19 from Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis
55. Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation
56. Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL
57. Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy
58. Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL
59. Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials
60. SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia
61. Self-reported positive impact of mentored clinical research training is associated with academic success in hematology
62. Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
63. Sex Therapy Frameworks and Sexual Problems, Dysfunctions, and Disorders
64. Adoption of pediatric‐inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population‐based study
65. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR
66. Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia
67. Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age
68. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia
69. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study
70. Late mortality and chronic health conditions in long-term survivors of early-adolescent and young adult cancers: a retrospective cohort analysis from the Childhood Cancer Survivor Study
71. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia
72. Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance)
73. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial
74. Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)
75. Real World Outcomes for AYA Patients with Relapsed/Refractory B-Cell ALL Receiving CD19-Directed CAR T-Cell Therapy
76. The Impact of Social Determinants of Health on Brexucabtagene Autoleucel Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
77. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial
78. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia.
79. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665
80. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
81. Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis
82. Introduction to JEE symposium on “What should go into the only economics course students will ever take?”
83. Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors
84. Single cell dissection of developmental origins and transcriptional heterogeneity in B-cell acute lymphoblastic leukemia
85. New Approaches to Treating Challenging Subtypes of ALL in AYA Patients
86. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
87. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes
88. Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival
89. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia
90. Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia
91. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults
92. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy
93. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia
94. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study
95. Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia
96. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
97. Taking a “BiTE out of ALL”: blinatumomab approval for MRD-positive ALL
98. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
99. Should immunologic strategies be incorporated into frontline ALL therapy?
100. MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.